Red Light Holland applauds the decision of Washington State's government to provide $200,000 in funding for psychedelics research.
Red Light Holland applauds the decision of Washington State's government to provide $200,000 in funding for psychedelics research.
UK-based Albert Labs announces its official trading date on Canada's CSE exchange. The Company will commence trading Thursday, March 11th under the symbol "ABRT"
Small Pharma announces two more planned clinical trials for 2022 from its pipeline of DMT-based drug candidates.
Incannex reports a strong clinical response in its trial of a cannabinoid combination product IHL-42X for sleep apnea.
Incannex Healthcare to incorporate virtual reality in a new R&D partnership aimed at psychedelics-based therapies.
Novamind announces it will conduct a Phase II clinical trial for the sponsor, Usona Institute, on a psilocybin-based therapy for MDD.
Seelos Therapeutics reports progress on several of its drug R&D initiatives, including preparing for a Phase IIb/Phase III trial of SLS-005 for ALS.
Field Trip Health announces a strategic partnership with Cerebral, "the fastest growing online mental health platform".
MindMed releases a peer-reviewed study that confirms the similar psychoactive effects of psilocybin and Lysergic Acid Diethylamide (LSD).
MINDCURE announces new formulations for its proprietary synthetic ibogaine, supported by a new patent application.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now